Swissmedic On Project Orbis: Faster Access To Drugs, Valuable Scientific Discussions
In the first of a two-part interview with the Pink Sheet, an expert from the Swiss drug regulator explains why international collaborations are “the future” and outlines the agency’s “extremely positive” experience since joining the Project Orbis initiative three years ago.
You may also be interested in...
In the second of a two-part interview with the Pink Sheet, an expert from the Swiss drug regulator discusses the similarities and differences between the ACCESS Consortium and Project Orbis, while the Canadian regulator also offers its perspective.
Several categories of pharmaceutical products, including those used to treat rare diseases, could be reimbursed three months faster than is typical in Switzerland under its new early access scheme.
Regulators from Canada, the UK and Australia discuss their experiences of working together under both the ACCESS Consortium, an international regulatory worksharing coalition, and Project Orbis, a parallel review process designed to speed up access to oncology medicines.